1. Use mixtures to make drugs for treating diseases or skin diseases. Requirement 1: a mixture of (a) dihydrofluorooctane sulfonate dehydrogenase (DHODH) inhibitors,And (b) an ethylene oxide inhibitor (COX). Claim 2: according to the combination of claim 1, DHODH inhibitors are selected from the following groups: leflounomida, teriflonida, vidofludimus, laquinimob, brequinar sodium, which are made of derivatives of amino acid (ISO) nicotinic acid formula (1): a G1 group represents a nitrogen atom or a child rights committee and The other group is CRC type； G2 represents a nitrogen atom or a CRD group； R1 represents a selected group of hydrogen atom, halogen atom, C1-4 tar group, which can be replaced by 1,2 or 3 substitutes selected from halogen atom and hydrogen Xi group, and C3-8 cyclopropyl compound group can be replaced by 1, 2 or 3 substitutes selected from halogen atom and hydrogen Xi group； R2 represents a selected group of hydrogen atom, halogen atom and hydroxyl group, C1-4 tar group can be selectively replaced by 1, 2 or 3 selected halogen atoms and hydroxyl substitutes, C1-4 alcox group, and 1, 2 or 3 selected halogen atoms and hydroxyl substitutes,C3-8 cyclopropyl compounds and C3-8 cyclopropyl compounds can be selectively replaced by 1, 2 or 3 selected substitutes for halogen atoms and hydrogen based compounds； RA, Rb and RC independently represent some groups selected from hydrogen atoms, halogen atoms and C1-4 tar groups, and can optionally be replaced by 1, 2 or 3 substitutes selected from halogen atom and hydrogen Xi group, and alcoxi C1-4 group can be replaced by 1, 2 or 3 substitutes selected from halogen atom and hydrogen Xi group； RD represents a selected group of hydrogen atom, halogen atom and hydroxyl group,C1-4 tar group can be selectively replaced by 1, 2 or 3 selected halogen atoms and hydroxyl substitutes, and C1-4 toxic oxygen group can be selectively replaced by 1, 2 or 3 selected halogen and hydroxyl substitutes, C3-8 cyclooxygenates a
